Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review
Abstract Mepolizumab, a humanized anti‐IL‐5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life. A 62‐year‐old man using high‐dose inhaled corticosteroid visited our hospit...
Gardado en:
| Principais autores: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Wiley
2023-06-01
|
| Series: | Respirology Case Reports |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1002/rcr2.1158 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|